Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes

Diabetes

Volumn 64, Issue 1, 2015, Pages 72-78

  Christensen, Mikkel ^a,b   Calanna, Salvatore ^a,c   Sparre Ulrich, Alexander H ^a,b   Kristensen, Peter L ^d   Rosenkilde, Mette M ^b   Faber, Jens ^a   Purrello, Francesco ^c   Van Hall, Gerrit ^a   Holst, Jens J ^b   Vilsbøll, Tina ^a   Knop, Filip K ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF CATANIA   (Italy)

^d HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; HYDROCORTISONE; INSULIN; NORADRENALIN; SODIUM CHLORIDE; ANTIDIABETIC AGENT; FATTY ACID; GLUCOSE BLOOD LEVEL; GLYCEROL; HORMONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FATTY ACIDS, NONESTERIFIED; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLYCEROL; HORMONES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; TREATMENT OUTCOME;

EID: 84920059625     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0440     Document Type: Article

References (25)

1. Holst JJ, Christensen M, Lund A, et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011;13(Suppl. 1):89-94
2. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 2003;114:115-121
3. Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-cell function. Diabetes 2011;60:1599-1607
4. Meier JJ, Gallwitz B, Siepmann N, et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798-801
5. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011;60:3103-3109
6. Christensen MB, Calanna S, Holst JJ, Vilsbøll T, Knop FK. Glucosedependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. J Clin Endocrinol Metab 2014;99:E418-E426
7. Gerich JE, Langlois M, Noacco C, Karam JH, Forsham PH. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973;182:171-173
8. Arbelaez AM, Xing D, Cryer PE, et al.; Diabetes Research in Children Network (DirecNet) Study Group. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes 2014;15:127-134
9. Christensen M, Knop FK, Vilsbøll T, et al. Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. Regul Pept 2010;163:96-101
10. Kristensen PL, Pedersen-Bjergaard U, Kjær TW, et al. Influence of erythropoietin on cognitive performance during experimental hypoglycemia in patients with type 1 diabetes mellitus: A randomized cross-over trial. PLoS ONE 2013;8: e59672
11. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes; 1994; 43 535-539
12. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87:1239-1246
13. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002;359:824-830
14. Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall G. IL-6 selectively stimulates fat metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab 2010;299:E832-E840
15. Wolfe RR. Isotope Tracers in Metabolic Research: Principles and Practice of Kinetic Analysis. 2nd ed. Hoboken, NJ, Wiley-Liss, 2005, p. 474
16. de Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008; 51:2263-2270
17. Chia CW, Carlson OD, Kim W, et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009;58:1342-1349
18. Lyssenko V, Eliasson L, Kotova O, et al. Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 2011;60:2424-2433
19. De Marinis YZ, Salehi A, Ward CE, et al. GLP-1 inhibits and adrenaline stimulates glucagon release by differential modulation of N- and L-type Ca2+ channel-dependent exocytosis. Cell Metab 2010;11:543-553
20. Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bülow J. Glucosedependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 2010;59:2160-2163
21. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000;66:91-103
22. Aaboe K, Knop FK, Vilsbøll T, et al. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 2009;94:603-608
23. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 1999;48:1198-1214
24. Vella A, Rizza RA. Application of isotopic techniques using constant specific activity or enrichment to the study of carbohydrate metabolism. Diabetes 2009; 58:2168-2174
25. American Diabetes Association. Standards of medical care in diabetes- 2014. Diabetes Care 2014;37(Suppl. 1):S14-S80